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Summary
Objective: To describe the clinical characteristics, treatment, and outcomes of
cryptococcosis in HIV-negative patients.
Methods: HIV-negative adult patients with positive culture for Cryptococcus neofor-
manswho attended Ramathibodi Hospital between 1987 and 2003were retrospectively
reviewed.
Results: During the 17 year review period, 40 HIV-negative patients with cryptococ-
cosis were identified. Of these, 37 patients hadmedical records available for study. The
mean age was 49  18 (range 16—83) years and 73%were female. Twenty-four patients
(65%) had associated underlying conditions. The most common associated conditions
included immunosuppressive drug treatment (41%), presence of systemic lupus erythe-
matosus (16%), malignancies (16%), and diabetes mellitus (14%). C. neoformans was
mainly recovered from cerebrospinal fluid (32%), blood (28%), and sputum/bronch-
oalveolar lavage/lung tissue (28%). Twenty-three patients (62%) had disseminated
cryptococcosis. Six of 14 patients with cryptococcal meningitis were asymptomatic.
About half of the patients were treated with amphotericin B and subsequent fluco-
nazole. Five patients (14%) were initially misdiagnosed and treated for tuberculosis or
bacterial infection. The overall mortality rate was 27%.
Conclusions: Cryptococcosis is not rare in HIV-negative patients. The mortality rate is
high. Early recognition of cryptococcosis and use of appropriate antifungal therapy in
these patients may improve clinical outcomes.
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Introduction ding yeast with capsules. Differentiation fromCryptococcosis in HIV patients 73Cryptococcosis is a disease caused by Cryptococcus
neoformans, an encapsulated yeast-like organism.
Cryptococcal infection occurs worldwide differ-
ences in geographical distribution, patient charac-
teristics, and clinical presentation have been
described.1,2 In most cases cryptococcosis is known
to be associated with acquired immunodeficiency
syndrome (AIDS), although it has been found in other
types of immunocompromised patients3 and it
sometimes causes disease in HIV-negative patients.
Indeed, some studies have shown that 10—40% of
HIV-negative patients with cryptococcosis have no
apparent immune deficiency.4,5 C. neoformans
causes human diseases ranging from asymptomatic
pulmonary colonization to life-threatening menin-
gitis and disseminated infection.6,7 The central ner-
vous system is the most common site of cryp-
tococcosis infection.
Since little is known about cryptococcosis in HIV-
negative patients, patient characteristics, clinical
features, and outcomes of cryptococcosis in these
patients may be different from those in HIV-positive
patients. Here we describe the clinical character-
istics, treatment, and outcomes of cryptococcosis in
HIV-negative patients.Table 1 Underlying medical conditions of 37 HIV-
negative patients with cryptococcosis.
Underlying conditionsa N (%)
Receiving immunosuppressive drugsb 15 (41)
Systemic lupus erythematosus 6 (16)
Malignancies 6 (16)
Diabetes mellitus 5 (14)
Chronic inflammatory
demyelinating disease
2 (5)
Cirrhosis 2 (5)
Others c 8 (22)
a Patients may have had more than one underlying condi-
tion.
b Chemotherapy, prednisolone, azathioprine, cyclophospha-
mide.
c Included one each: nephrotic syndrome, polymyalgia rheu-
matica, idiopathic thrombocytopenic purpura, autoimmune
hemolytic anemia, hypothyroidism, aqueductal stenosis, tha-
lassemia, myasthenia gravis.Patients and methods
Patients
We retrospectively reviewed the medical records of
adult patients (15 years old) with positive culture
for C. neoformans who had attended Ramathibodi
Hospital (an 800-bedmedical school hospital in Bang-
kok, Thailand) at some time between January 1987
and December 2003. The data included clinical fea-
tures, underlying conditions, laboratory findings,
clinical diagnosis, treatment, and outcome. The
diagnosis of cryptococcosis was based on isolation
of C. neoformans from a normally sterile site, from
operative samples of pus, or from tissue obtained
from a site of focal suppuration. All cases had doc-
umentation of negative results from testing for the
anti-HIV antibody. Disseminated cryptococcosis was
defined by the presence of more than one site of
positive culture for C. neoformans or one site of
positive culture forC. neoformans (apart fromblood)
plus a positive test for serum cryptococcal antigen.
Identification of C. neoformans
C. neoformans was identified based on the charac-
teristic structural appearance of narrow-based bud-Candida species was made by testing for urease
production and, when grown on chlamydospore agar,
lack of pseudohyphae. Confirmation of C. neofor-
mans was made by measuring carbon and nitrogen
assimilationwith the agar discmethod. The presence
of cryptococcal antigen in the blood and cerebrosp-
inal fluid was determined by using the cryptococcal
antigen latex agglutination system (CALAS; Meridian
Diagnostic Inc, Cincinnati, Ohio, USA).Results
Clinical presentations and manifestations
During the 17 year review period, 40 HIV-negative
patients with cryptococcosis were identified, of
whom 37 had medical records available for study.
The mean age was 49  18 (range 16—83) years.
Twenty-seven patients (73%) were female. Twenty-
four patients (65%) had associated underlying med-
ical conditions. Common underlying conditions were
immunosuppressive drug treatment (41%), systemic
lupus erythematosus (16%), malignancies (16%), and
diabetes mellitus (14%) (Table 1). Presenting symp-
toms at the time of diagnosis of cryptococcosis were
reported in a total of 30 patients (81%). Fever (57%)
was the most common symptom followed by cough
(35%) and shortness of breath (27%) (Table 2).
Microbiologic characteristics and
laboratory findings
C. neoformans was discovered in the cerebrospinal
fluid of 12 patients (32%), in the blood of 11 patients
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Table 2 Clinical presentations of 37 HIV-negative
patients with cryptococcosis.
Symptomsa N (%)
Fever 21 (57)
Cough 13 (35)
Shortness of breath 10 (27)
Headache 9 (24)
Altered mental status 8 (22)
Nausea/vomiting 5 (14)
Diplopia 3 (8)
Skin and soft tissue swellingb 3 (8)
Diarrhea 2 (5)
Hemoptysis 2 (5)
Blurred vision 2 (5)
Pleuritic pain 1 (3)
a Patients may have had more than one clinical presenta-
tion.
b Two patients developed subacute osteomyelitis (Figure 2)
and one patient was diagnosed with a scalp abscess.
Figure 1 A 72-year-old woman presented with dry
cough, dyspnea, and alteration of consciousness. Chest
radiography showed patchy and nodular infiltration at
right upper lung (white arrow).(30%), in the sputum/bronchoalveolar lavage/lung
tissue in 11 patients (30%), in the skin and soft tissue
of three patients (8%), in the ascites fluid of two
patients (5%), and in the joint fluid, lymph node, and
stool of one patient each. Eleven patients (30%) had
more than one site of positive cultures. A serum
cryptococcal antigen test was performed in 24
patients, and 16 of these patients (66%) had positive
results with titers ranging from 1:4 to >1:1024.
Twenty-three patients (62%) had disseminated cryp-
tococcal infection. Of these, 17 patients were
female.
Lumbar puncture was performed in 25 patients at
the time of diagnosis. Fourteen of these patients
(56%) were found to have cryptococcal meningitis
and six patients were asymptomatic. The opening
pressure was documented for nine patients, with a
median of 27 (range 8—58) cmH2O. Five patients had
an opening pressure of more than 20 cmH2O. Median
cerebrospinal fluid white blood cell count was 89
(range 0—950)  106 cells/l with a median 92%
mononuclear cells (range 82—100). Median cere-
brospinal fluid protein and glucose levels were 94
(range 28—240) mg/dl and 50 (range 8—138) mg/dl,
respectively. Themedian ratio of cerebrospinal fluid
to plasma glucose was 0.29 (range 0.06—0.87). A
cerebrospinal fluid cryptococcal antigen test was
performed in 24 patients; 17 patients (71%) had a
positive result, with titers ranging from 1:4 to
>1:1024. India ink preparation was positive in six
of 11 patients (55%).
Chest radiography findings in 35 patients included
nine normal patients (26%), reticulonodular or reti-
cular or fibroreticular infiltrations in nine patients
(26%), interstitial infiltrations in seven patients
(20%), pulmonary nodules in six patients (17%),mass-like lesions in two patients (6%), cavitary
lesions in two patients (6%), and pleural effusion
in one patient (3%) (Figure 1).
Treatment and outcomes
Eighteen patients (49%) were treated with ampho-
tericin B and subsequent oral fluconazole; seven
patients (19%) were treated with only amphotericin
B; four patients (11%) were treated with amphoter-
icin B plus flucytosine; and three patients (8%) were
treatedwithonlyoralfluconazole.Themediancumu-
lative dose of amphotericin B was 800 mg (range 40—
4000 mg) and themedian duration of oral fluconazole
treatment was 90 days (range 15—1080 days). Five
patients (14%) were not treated with any antifungal
drugs because they were initially misdiagnosed;
three of these were treated for tuberculosis and
two patients were treated for bacterial infection.
Of these, three patients died (Patient Nos 3, 5, 10;
Table 3). Nine patients (24%) required surgical inter-
vention as well as antifungal therapy. The surgical
procedures includedventriculoperitoneal shunt (four
patients), lobectomy or segmental resection of lung
parenchyma (three patients), sequestrectomy and
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Table 3 Baseline characteristics, clinical presentation boratory findings, and treatment of 10 patients who died.
No. Age, sex Underlying
condition
Imm -suppressive
drug
Site of positive culture
for C. neoformans
Cryptococcal antigen
titer (body fluid)
Antifungal treatment
(duration)
1 69, M CIPD, DM Pred lone Ascites, CSF 1:64 (blood)
>1:1024 (CSF)
AmB (2 weeks) followed
by Flu (8 weeks)
2 64, F Breast cancer, cirrhosis — Ascites — AmB (1 day)
3 21, F SLE Pred lone, azathioprine Blood — No
4 41, F Lymphoma Chem herapy Blood, CSF Positive (blood) AmB (6 days)
5 68, F — — Sputum, urine — No
6 54, F — — Blood, bone marrow 1:8 (blood) AmB (3 days) followed
by Flu (4 weeks)
7 68, F Multiple myeloma Pred lone, chemotherapy Blood — AmB (2 days)
8 43, F Myasthenia gravis, SLE Pred lone CSF >1:1024 (blood),
>1:1024 (CSF)
AmB (10 weeks)
9 74, M AIHA, CIDP Pred lone,
cyclo osphamide
Blood, bronchoalveolar
lavage
— AmB (5 days)
10 74, M — — Sputum — No
Abbreviations: AmB = amphotericin B, AIHA = autoimmune hem tic anemia, CSF = cerebrospinal fluid, CIPD = chronic inflammatory polyradiculopathy, Flu = fluconazole, F = female,
DM = diabetes mellitus, LN = lymph node, M = male, SLE = syste lupus erythematosus.
Table 4 Baseline characteristics, clinical presentations boratory findings, and treatment of two patients with a relapse of the disease.
No. Age, sex Underlying
condition
Immuno-suppressive
drug
e of positive culture
r C. neoformans
Cryptococcal antigen titer (body fluid) Antifungal treatment
(duration)
t episode 2nd episode 1st episode 2nd episode
1 62, F DM Prednisolone F CSF 1:32 (CSF) 1:32 (CSF) 1st episode: AmB (3 weeks)
plus 5-FC (6 weeks)
2nd episode: AmB (6 weeks)
plus 5-FC (6 weeks)
followed by Flu (24 weeks)
2 16, M Acute
leukaemia
Chemotherapy ood,
ne marrow
CSF 1:256 (blood) positive (CSF) 1:256 (CSF) 1st episode: AmB (3 weeks)
followed by Flu (4 weeks)
2nd episode: liposomal AmB
(6 weeks) followed by Flu
(24 weeks)
Abbreviation: AmB = amphotericin B, CSF = cerebrospinal fluid, = fluconazole, F = female, DM = diabetes mellitus, M = male.s, la
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Figure 2 An 83-year-old woman presentedwith pain and
swelling at right middle finger for 10 days. Radiography of
right hand showed soft tissue swelling and osteolytic
lesion at middle finger (white arrow).debridement of bone (two patients), and incision
with debridement of localized abscess (one patient).
One patient required two operations. Four patients
(11%) did not receive a follow up. Two (5%) patients
hada relapse of thedisease. Baseline characteristics,
clinical presentation, laboratory findings, and treat-
ment are summarized in Table 4. The overall mortal-
ity rate was 27%. Among 10 patients who died,
baseline characteristics, clinical presentations,
laboratory findings, and treatment are summarized
in Table 3. Seven patient deaths were related to
cryptococcosis (Figure 2).
Discussion
Before the AIDS epidemic, the number of cryptococ-
cal infections in immunocompetent and immunocom-
promised hosts was roughly equal.8 The decreasing
incidence of cryptococcosis amongpatientswith AIDS
has been documented as being due to antiretroviral
therapy. Cryptococcosis is still an important issue in
HIV-negative patients, including patients with under-
lying medical conditions or predisposing factors.An underlying immunosuppressed condition was
identified in about half of our patients, a rate
similar to that in other reports.9,10 Cell-mediated
immunity with CD4 T-lymphocyte is an important
mechanism in defense against this fungus.11 Being a
recipient of immunosuppressive drug treatment
was themost common associatedmedical condition
in our study. Other predisposing conditions asso-
ciated with cryptococcosis in HIV-negative patients
have been reported, such as organ transplantation,
Cushing’s syndrome, chronic leukemia, lymphoma,
cirrhosis, chronic renal failure, or diabetes.12—14
However, approximately one-third of our patients
had no known underlying medical conditions. These
data are similar to the findings from a previous
study.13 In most reports there were more males
than females among HIV-negative patients with
cryptococcosis.13—15 This, however, was not the
case for our patients, where the majority were
female with systemic lupus erythematosus being
treated with immunosuppressive agents. It has
been suggested that a possible explanation for
the gender difference could be a difference in
the host’s immune response between men and
women.16 Although more female patients had dis-
seminated infection and died, we could not con-
clude that being female was a predictive factor of
mortality because this was a retrospective study
with too few patients (odds ratio 0.817; 95% con-
fidence interval 0.164—4.058).
In our study, meningitis was the most common
presenting symptom and six patients were asympto-
matic. Asymptomatic meningitis has been men-
tioned as being of possible use in early diagnosis
of the disease.17 A study has shown that patients
with an immunosuppressed condition, especially T-
cell suppression, may present with less typical clin-
ical manifestations of meningitis.14 For this reason
lumbar puncture is important in patients with cryp-
tococcosis even when no central nervous system
symptoms are seen. It has been recommended that
all patients with cryptococcal diseases should
undergo lumbar puncture to exclude concurrent
central nervous system infection.18 Asymptomatic
meningitis may have been under-recognized in
our study because only two-thirds of our patients
underwent lumbar puncture.
According to a previous study, disseminated cryp-
tococcosis commonly occurs in immunocompromised
patients, particularly in HIV-positive patients, and
rarely in immunocompetent patients.19 However,
of our 23 patients with disseminated cryptococcal
diseases, eight patients were apparently immuno-
competent. This finding emphasizes the need for
awareness of disseminated cryptococcosis among
patients with no underlying medical condition.
Cryptococcosis in HIV patients 77A broad spectrum of X-ray manifestations of
pulmonary disease can be observed. Pulmonary
nodules and masses were the predominant mani-
festations of pulmonary cryptococcosis in HIV-
negative patients in previous reports.20,21 By con-
trast, interstitial, reticulonodular, reticular, and
fibroreticular infiltration patterns were common
findings in our patients. This may be explained by
the higher frequency of disseminated disease in
our study.
Two of 10 patients who died had high initial
antigen titer (>1:1024). We could not conclude that
there was any strong relationship between initial
antigen titer and mortality or relapse.
The Infectious Disease Society of America guide-
lines for management of cryptococcal diseases has
made recommendations on the dosage of antifungal
drugs and the duration of therapy.18 The treatment
option for cryptococcosis depends on the site of
infection and the underlying condition of the
patient. The duration of fluconazole treatment of
our patients varied depending on the patient’s clin-
ical manifestations, underlying conditions, and
laboratory findings. Because flucytosine has only
been available in Thailand for the last ten years,
only four patients were treated with amphotericin B
plus flucytosine, which some recognize to be a
preferred regimen for cryptococcal meningitis in
both HIV-negative and HIV-positive patients.18
Occasionally, medical therapy alone may not cure
the disease. Surgical treatment should be used as an
adjunctive therapy in cases of localized abscess and
osteomyelitis. Three patients underwent lobectomy
or segmental resection because physicians could not
differentiate cryptococcoma from tumor or malig-
nancy. Although several treatment options for
managing elevated intracranial pressure are recom-
mended,18 ventriculoperitoneal shunt was per-
formed in our patients due to persistently
elevated intracranial pressure despite repeating
the lumbar puncture.
The limitations of our retrospective study are the
small sample size (because only culture-positive
patients were included), the absence of typing of
cryptococcal varieties, and the lack of systematic
investigations of disseminated infection by means of
lumbar puncture, serum, and cerebrospinal fluid
cryptococcal antigen tests.
In summary, cryptococcosis is not rare, as pre-
viously thought, in HIV-negative patients. It should
be recognized as a possible cause of meningitis and
pulmonary infection even in HIV-negative patients,
though especially in patients with underlying immu-
nocompromised conditions. Cryptococcal antigen
tests may be helpful, but culture is needed for
diagnosis. Early recognition of cryptococcosis andintroduction of appropriate antifungal therapy in
these patients may improve clinical outcomes.
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